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Background: Rarely, patients with pathological complete response (PCR) after neoadjuvant chemo-
radiotherapy demonstrate acellular mucin pools. The prognostic signiﬁcance of this ﬁnding is contro-
versial. The objective of this study was to determine impact of acellular mucin pools on disease free and
overall survival in patients with complete pathological response to neoadjuvant chemoradiotherapy in
rectal cancer. Methods: One hundred and seventy two patients received neoadjuvant chemo-
radiotherapy for rectal cancer and underwent surgery. Patients were divided into two groups based on
presence of acellular mucin pools. Locoregional failures, distant failures and deaths were compared.
Expected 5 year disease free and overall survival was calculated. Results: Median follow-up was 36(4
e94) months. Complete pathological response was identiﬁed in 35(20.3%) patients. Of these, 12(34.2%)
had acellular mucin pools in resected specimen. Majority of mucin negative tumors were moderately
differentiated (78% vs 25%) (P ¼ 0.005). Median overall survival for mucin positive and mucin negative
tumors was 4(1.3e5.7) and 3.3(0.1e6.3) years respectively. Expected 5 year disease free and overall
survival for mucin positive and mucin negative tumors was 73% and 89% (P ¼ 0.1) and 75% and 87%
(P ¼ 0.4). Conclusion: Acellular mucin pools in rectal cancer following a PCR to neoadjuvant treatment
do not impact survival.
© 2014 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
Preoperative chemoradiotherapy has emerged as the standard
of care in locally advanced rectal cancer [1]. It improves resect-
ability, sphincter preservation and negative margin rates in rectal
cancer [1e3]. Complete pathological response (PCR) to preopera-
tive chemoradiotherapy varies between 10 and 20% [4]. A PCR has
been linked to improved outcomes. What is not well deﬁned is theorial Cancer Hospital and
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specimen after complete pathological response to preoperative
chemoradiotherapy. Joint consensus statement by American Col-
lege of Pathologists recommends not considering acellular mucin
pools as residual tumor but the evidence for this recommendation
is lacking [5]. Very few studies have speciﬁcally dealt with this topic
and their results are conﬂicting compounded by small sample size.
Without standardization of criteria of pathological response, results
of future prognostic studies and trials would be difﬁcult to inter-
pret. At present, it is not clear whether presence of acellular mucin
pools in resected rectal cancer after preop chemoradiotherapy have
Table 1
Patient characteristics.
Number (N ¼ 12) Percent % Number (N ¼ 23) Percent % P value
Gender Male 8 67 12 52 0.4
Female 4 33 11 48
Family history Yes 0 0 1 4 0.4
No 12 100 22 96
Clinical tumor size I 1 8 2 8 0.8
II 8 67 17 74
III 3 25 4 18
Clinical nodal stage N0 3 25 2 9 0.2
N1 1 8 6 26
N2 8 67 15 65
Distance from anal verge (centimeter) 5 cm 7 59 16 69 0.8
6e10 cm 4 33 6 27
>10 cm 1 8 1 4
Surgical procedure Low anterior resection 6 50 9 39 0.8
Ultra low anterior resection 1 8 3 13
Abdominoperineal resection 5 42 10 44
Others 0 0 1 4
Grade Well 4 33 1 4 0.005
Moderate 3 25 18 79
Poor 2 17 2 9
Mucinous 3 25 1 4
Others 0 0 1 4
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surgery.
The objective of this study was to determine impact of presence
of acellular mucin pools in resected specimen of rectal cancer on
disease free and overall survival after complete pathological
response to neoadjuvant chemoradiotherapy.Table 2
Failures (locoregional and distant) and deaths in patients with and without acellular











Locoregional 1 8 0 e 0.3
Distant 2 16 1 4 0.2
Deaths 3 25 3 13 0.52. Methods
During a seven year period from 2005 to 2011, a total of 182
patients underwent resection for underlying rectal cancer. All pa-
tients had non metastatic rectal cancer. Patients were discussed in
multi-disciplinary meeting and a treatment plan was devised.
Thirty four patients did not receive preoperative chemo-
radiotherapy and were excluded from the study. Eighty nine pa-
tients received induction chemotherapy followed by concurrent
chemoradiotherapy before surgery while rest had various combi-
nations of preoperative chemo and radiotherapy. Capecitabine
based preoperative chemotherapy was used in 114 while 5-
Flourouracil based regimen was used in 34 patients. Complete
pathological response was deﬁned according to AJCC guidelines as
absence of tumor cells in resected rectal specimen or draining
lymph nodes. Out of 148 patients, 35 had complete pathological
response (pCR) to neoadjuvant treatment. These patients were
included in the study and were divided into two groups based on
presence of acellular mucin pools in resected rectal specimen. Pa-
tient demographics, clinical stage at presentation, histopathological
characteristics of tumor and distance from anal verge were
compared. Number of locoregional and distant failures and deaths
observed during the follow-up period was compared.
Chi square test was used for categorical variables while t test
was used for interval variables. Disease free survival was calculated
by subtracting date of local, regional or distant recurrence from
date of surgery. Overall survival was calculated by subtracting date
of death/last follow-up from date of surgery. Expected 5 year sur-
vival was calculated using Kaplan Meier curves and signiﬁcance
was determined using Log rank test. A P value <0.05 was consid-
ered signiﬁcant. SPSS version 20 was used for statistical analysis.
The hospital ethics committee granted exemption from formal re-
view of this study.3. Results
3.1. Patient characteristics
Median follow-up was 36(4e94) months. Complete patholog-
ical response was observed in 35(21%) patients. Out of these, 12
patients had acellular mucin pools on histopathological examina-
tion of resected specimen. No difference was observed between 2
groups with respect to preoperative tumor and nodal stage. Choice
of surgical procedure and distance from anal verge was not
signiﬁcantly different between the two groups. A signiﬁcant dif-
ference was observed with respect to grade of tumors and
moderately differentiated tumors were seen more frequently in
patients with absence of mucin pools (78% vs 25%) (P ¼ 0.005). Out
of 4 patients with mucinous tumors on pre-treatment biopsy,
3(75%) had acellular mucin pools in resected specimen as shown in
Table 1.
3.2. Relapse and mortality
Table 2 represents relapse and mortality. No locoregional
relapse was observed in patients with absent acellular mucin pools.
One patient with mucin pools had a locoregional relapse. This pa-
tient was diagnosed with mucinous adenocarcinoma on endo-
scopic biopsy before initiation of treatment. Similarly no signiﬁcant
difference was observed between 2 groups with respect to distant
relapse and deaths.
3.3. Survival
Median overall survival for mucin positive and mucin negative
tumors was 4(1.3e5.7) and 3.3(0.1e6.3) years respectively.
Fig. 1. Expected 5 year disease free survival in patients with and without acellular
mucin pools after complete pathological response to neoadjuvant chemoradiotherapy.
A.B.H. Bhatti et al. / International Journal of Surgery 12 (2014) 1123e1126 1125Expected 5 year disease free survival was 73% and 89% and overall
survival was 75% and 87% in mucin positive and mucin negative
tumors respectively as shown in Figs. 1 and 2. No signiﬁcant dif-
ference was observed between the two groups with respect to
disease free and overall survival.
4. Discussion
Signiﬁcance of acellular mucin pools has been a subject of
debate and very few studies have attempted to answer this ques-
tion. In the current study, no signiﬁcant difference in adverse
events in patients with PCR with and without acellular mucin pools
was observed. Overall, patients with a pCR had excellent 5 year
actuarial disease free and overall survival. A signiﬁcant number of
patients underwent induction chemotherapy before concurrent
chemoradiotherapy. Limitations of the study include its retro-
spective design and small sample size. It cannot be ruled out that
disease free and overall survival between the two groups were not
signiﬁcantly different because of the small sample size.
The pCR rate in rectal cancer after neoadjuvant treatment
varies between 10 and 20% [3,4,6,7]. Furthermore, out of patientsFig. 2. Expected 5 year overall survival in patients with and without acellular mucin
pools after complete pathological response to neoadjuvant chemoradiotherapy.who achieve a pCR, 15e30% demonstrate acellular mucin pools
[8,9]. This results in a small group with pCR þve/acellular
mucin þve tumors. There are only 4 reports in literature that deal
speciﬁcally with impact of acellular mucin pools after pCR to
neoadjuvant treatment in rectal cancer and the number of patients
range from 11 to 35 [8,9,10.11]. Lobato and colleagues in their
study analyzed 58 patients with PCR after chemoradiotherapy.
Eleven patients had acellular mucin pools. Disease free survival
(79% vs 95%) and overall survival (83% vs 95%) was lower in pa-
tients with acellular mucin pools but did not reach statistical
signiﬁcance. No signiﬁcant difference in interval to surgery was
observed between the two groups. They concluded that acellular
mucin pools are associated with aggressive biology [10]. Lim and
colleagues examined 217 specimens with PCR of which 35(16%)
had acellular mucin pools. They found a signiﬁcant association
between acellular mucin pools and male gander, mucinous his-
tology and interval to surgery (<42 days). The 3 year overall sur-
vival (96.8% vs 95.9%) and disease free survival (97% vs 93%) was
similar in mucin þve and ve specimens respectively [11]. In the
present study, 5 year survival was determined and no signiﬁcant
difference in distribution between mucin pools and gender was
observed. A signiﬁcant majority of specimen with eve mucin had
well/moderately differentiated tumors when compared with þve
mucin specimen (82.6% vs 58.3%).
Studies on signiﬁcance of acellular mucin pools are limited by
small sample size. The number of patients who achieve a PCR and
have acellular mucin pools is generally very small. The problem
however has a signiﬁcant impact on decisions. For example a
medical student underwent preoperative chemoradiotherapy for
rectal carcinoma starting close to dentate line and had excellent
clinical response. Although patient was planned for abdomi-
noperineal resection, she refuted the idea of a permanent co-
lostomy. It was decided to give her a chance and have a
Hartman's procedure performed. If there was a PCR in excised
specimen, she could undergo reversal of colostomy later. Fortu-
nately, she had a PCR but with mucin pools on the edge of
resected specimen. The best evidence for management in these
patients is limited to a few retrospective studies with small
sample size. It is possible that acellular mucin pools represent an
aggressive biology but till date no signiﬁcant difference has been
noted. It has been suggested that a PCR is linked to improved
outcomes [12,13]. It has also been suggested that colloid type
response or mucin pools in rectal cancer is linked to radiation
therapy [8,14e16]. How radiation leads to development of acel-
lular mucin pools in specimens with PCR is unknown. Further-
more, the notion that mucin pools are seen only in patients with
poorly differentiated/mucinous neoplasms is incorrect. All pre-
viously conducted studies have shown that well/moderately
differentiated tumors can also have acellular mucin pools in the
specimen after preoperative chemoradiotherapy. In the current
study, 75% specimens with a pre-chemoradiotherapy mucinous
histology had acellular mucin pools in resected specimen vs 29%
for all other histologies.
All these studies provide preliminary evidence to non-signiﬁ-
cant impact of mucin pools without tumor cells in prognosis of
rectal cancer. Large scale multi center studies with data collected in
a prospective fashion are needed. Until then, these studies should
help in making treatment decisions in patients with rectal cancer
and acellular mucin pools.Ethical approval
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